Rubius Therapeutics to Announce Third Quarter 2018 Financial Results
The company will not be conducting a teleconference in conjunction with its financial results press release.
About Rubius Therapeutics
Rubius Therapeutics is a biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM™ was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and ready-to-use cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of rare diseases, cancer and autoimmune diseases by leveraging three distinct therapeutic modalities — cellular shielding, potent cell-cell interaction and tolerance induction. For more information, visit www.rubiustx.com, or follow us on Twitter and LinkedIn.
+1 (973) 271-6085
Vice President, Corporate Communications and Investor Relations
+1 (617) 229-6122
Source: Rubius Therapeutics